Searching For Real Value In Market Debris At Ginkgo Bioworks Holdings Inc (NYSE: DNA)

Jeremiah Abramson

After Hours

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.

Stocks Info

As a NYSE listed company, DNA falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Ginkgo Bioworks Holdings Inc is $721.65M. A total of 1.04 million shares were traded on the day, compared to an average of 1.61M shares.

In the most recent transaction, Coen Steven P. sold 1,312 shares of DNA for 13.65 per share on Oct 17 ’25. After the transaction, the insider now owns 6,738 company shares. In a previous transaction on Oct 21 ’25, Coen Steven P. bought 5,609 shares at 15.00 per share.

Among the insiders who bought shares, Coen Steven P. acquired of 1,312 shares on Oct 21 ’25 at a per-share price of $13.65. In another insider transaction, Che Austin bought 2,200 shares at $15.21 per share on Oct 08 ’25.

In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, DNA has a high of $17.58 and a low of $5.00.

As of this writing, DNA has an earnings estimate of -$1.24 per share for the current quarter. EPS was calculated based on a consensus of 3.0 estimates, with a high estimate of -$1.21 per share and a lower estimate of -$1.27. The company reported an EPS of -$1.08 in the last quarter

Balance Sheet Annually/Quarterly

The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. DNA’s latest balance sheet shows that the firm has $1.55B in Cash & Short Term Investments as of fiscal 2021. There were $23.03M in debt and $134.76M in liabilities at the time. Its Book Value Per Share was $11.69, while its Total Shareholder’s Equity was $1.57B.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNA is Buy with a score of 2.40.

Park Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.